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ABSTRACT
Background BirteHoggeDube ´ syndrome (BHDS) is an
inherited autosomal genodermatosis characterised by
ﬁbrofolliculomas of the skin, renal tumours and multiple
lung cysts. Genetic studies have disclosed that the
clinical picture as well as responsible germline FLCN
mutations are diverse.
Objectives BHDS may be caused by a germline deletion
which cannot be detected by a conventional genetic
approach. Real-time quantitative polymerase chain
reaction (qPCR) may be able to identify such a mutation
and thus provide us with a more accurate clinical picture
of BHDS.
Methods This study analysed 36 patients with multiple
lung cysts of undetermined causes. Denaturing high
performance liquid chromatography (DHPLC) was applied
for mutation screening. If no abnormality was detected
by DHPLC, the amount of each FLCN exon in genome
was quantiﬁed by qPCR.
Results An FLCN germline mutation was found in 23
(63.9%) of the 36 patients by DHPLC and direct
sequencing (13 unique small nucleotide alterations which
included 11 novel mutations). A large genomic deletion
was identiﬁed in two of the remaining 13 patients by
qPCR (one patient with exon 14 deletion and one patient
with a deletion encompassing exons 9 to 14). Mutations
including genomic deletions were most frequently
identiﬁed in the 39-end of the FLCN gene including exons
12 and 13 (13/25¼52.0%). The BHDS patients whose
multiple cysts prompted the diagnosis in this study
showed a very low incidence of skin and renal
involvement.
Conclusions BHDS is due to large deletions as well as
small nucleotide alterations. Racial differences may occur
between Japanese and patients of European decent in
terms of FLCN mutations and clinical manifestations.
INTRODUCTION
BirteHoggeDubé syndrome (BHDS) is a rare, auto-
somal dominant inheritance genodermatosis charac-
terisedbymultiple,asymptomatic,domeshapedskin
papules involving the head, neck, chest, back, and
arms.
1 These skin manifestations are pathologically
characterised as ﬁbrofolliculomas, or hamartomas of
the hair follicles.
12BHDS is associated with heredi-
tary renal tumours, especially hybrid oncocytic renal
tumours and chromophobe renal cell carcinoma, as
well as with pneumothoraces and/or multiple lung
cysts.
3e5 A risk assessment study of BHD affected
patients concluded that a diagnosis of BHDS
conferred a 6.9-fold increased risk of developing renal
neoplasia and a 50.3-fold increased risk of sponta-
neous pneumothorax.
6 The folliculin gene (FLCN),
also known as BHD, that lies within the chromo-
somal band 17p11.2 is mutated in patients with
BHDS.
7 The FLCN gene consists of 14 exons
7 and is
considered to be a tumour suppressor gene.
8
Genetic testing, however, has disclosed that
patients with BHDS show a clinical heterogeneity
and do not always have the three characteristic
phenotypes (involvement of skin, kidney, and
lung). An isolated familial spontaneous pneumo-
thorax without skin and renal involvements is
caused by FLCN germline mutations.
9e11 Among
the three manifestations, lung involvement may be
the earliest since spontaneous pneumothorax was
reported to occur at 7 years of age in a patient with
BHDS.
12
This study extended our previous study
10 and
analysed the FLCN gene in patients with multiple
cysts and/or spontaneous pneumothorax due to
undetermined causes. A real-time quantitative
polymerase chain reaction (qPCR) system was
established for genetic testing of the FLCN gene
since some patients with BHDS may have a large
genomic deletion like other hereditary genetic
disorders.
13e16 The results demonstrated, for the
ﬁrst time, that not only a small nucleotide alter-
ation, but also a genome deletion, causes BHDS and
its clinical phenotype can be solely or mainly
expressed in the lungs.
SUBJECTS AND METHODS
Study population
This study was approved by the ethics committees
of Juntendo University. All patients who partici-
pated in this study provided their written informed
consent. As previously reported, this was an
extended study
10 to analyse the FLCN gene in
patients who had multiple lung cysts of undeter-
mined causes with or without pneumothorax
episodes. This study assessed 36 patients including
14 males and 22 females (the age at the ﬁrst
pneumothorax and the enrolment, 35.1615.3 and
48.1615.0 years old, respectively, mean6SD). Nine
of 36 patients were smokers. They were enrolled for
this study since multiple lung cysts were demon-
strated by chest computed tomography (CT) when
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Mutation reportthey had a pneumothorax or were noted to have an abnormality
on their chest x-rays during a regular health check-up (for details
see supplementary ﬁle).
Mutation analysis of the FLCN gene
Mutations of the FLCN gene were ﬁrst screened by denaturing
high performance liquid chromatography (DHPLC) followed by
the direct sequencing of the FLCN exon which was suspected to
have a mutation.
10 If sequence alterations were located in the
region of the splice signal sequence and supposed to affect
mRNA splicing, reverse transcription of FLCN mRNA followed
by PCR (RT-PCR) was performed using ThermoScript RT-PCR
system (Invitrogen, Carsbad, California, USA).
10 The primers
used for RT-PCR are listed in supplementary table 1.
If no abnormality was detected by DHPLC, then the copy
number of each exon of the FLCN gene in the genome was
quantiﬁed using real-time qPCR to detect a large genomic dele-
tion in the FLCN gene. The DNA copy number of 14 exons of
the FLCN gene (exons 1 to 14) was determined with an iCycler
real-time PCR detection system (Applied Biosystems, Foster
City, California, USA) using the DNA binding dye SYBR Green
I. If qPCR indicated a germline deletion in the FLCN gene,
Southern blotting was performed to conﬁrm the qPCR result
(see supplementary ﬁle and supplementary table 1 listing the
primers for qPCR).
Nucleotide alterations were described relative to a reference
sequence of coding DNA according to the nomenclature
recommended by den Dunnen and Antonarakis
17: the nucleotide
+1 in the coding DNA sequence of FLCN is the A of the ATG
translation initiation codon.
RESULTS
Germline mutation of the FLCN gene
An FLCN germline mutation was found in 23 (63.9%) of the 36
patients by DHPLC. The remaining 13 patients were examined
by qPCR, and a genomic deletion was found in two patients
(15.4%). Accordingly, an FLCN germline mutation was found in
25 (69.4%) of the 36 patients with multiple lung cysts (table 1).
DHPLC screening resulted in the identiﬁcation of 13 unique
mutations including three nonsense mutations, four deletions,
two insertions, one composite mutation consisting of insertion
and deletion, and three splice acceptor site mutations. No
missense mutation was identiﬁed in the study population.
Eleven of them were novel (supplementary ﬁgures 1 and 2). Five
mutations including two splice acceptor site mutations were
expected to cause abnormalities in FLCN mRNA splicing. The
effect of a mutation on FLCN mRNA transcripts was examined
using EpsteineBarr virus lymphoblastoid B cell line (EBV-LCL)
established from the patient using RT-PCR,
10 which conﬁrmed
that all ﬁve mutations generated the exon skipped transcript
together with normally spliced transcript (supplementary ﬁgure
2). Most of the mutations identiﬁed in this study were expected
to cause a frameshift leading to the premature protein trunca-
tion, but c.769e771delTCC and three of ﬁve mutations within
the region of the splice signal sequence (supplementary ﬁgures
2AeC) were expected to cause in-frame amino acid deletions
(table 1).
A large genomic deletion in the FLCN gene was identiﬁed in
two patients, c.872-?_c.1740+?del and c.1539-?_c.1740+?del,
using qPCR (ﬁgure 1). Patient JBR14 showed a decreased haploid
copy number close to 0.5 in exons 9 to 14, suggesting a large
genomic deletion spanning from exons 9 to 14. On the other
hand, JBR18 showed a decreased haploid copy number close to
0.5 only in exon 14, suggesting a genomic deletion including
exon 14 and 39-untranslated region. These ﬁndings were
conﬁrmed with a conventional Southern blotting analysis
(ﬁgure 2). BamHI digestion of normal controls generated a single
positive fragment (ﬁgure 2A; 13917 bp in size as expected in
ﬁgure 2B) since other fragments are expected not to show up due
to their small sizes. In patients JBR18 and JBR14, a smaller
fragment, (a) and (b) in ﬁgure 2A, respectively, were
Table 1 The results of mutation analysis of the FLCN gene
Patient Location Mutation Predicted results
JBR4 Exon 10 c.1063-10_1065delTCTTGTTTAGGTC Exon 10 skip (38 amino acid in-frame deletion)
JBR7 Exon 10 c.1063-10_1065delTCTTGTTTAGGTC Exon 10 skip (38 amino acid in-frame deletion)
JBR8 Exon 13 c.1533G/A (W511X) Protein truncation
JBR9 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR10 Exon 7 c.769_771delTCC In-frame deletion
JBR11 Exon 9 c.887C/A (S296X) Protein truncation
JBR12 Exon 13 c.1533_1536delGATG Frame shift, protein truncation
JBR13 Exon 13 c.1433-1G/T Exon 13 skip (frame shift, protein truncation)
JBR14 Exon 9 w 14 c.872-?_c.1740+?del Protein truncation
JBR15 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR16 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR17 Exon 10 c.1063-2A/G Exon 10 skip (38 amino acid in-frame deletion)
JBR18 Exon 14 w c.1539-?_c.1740+?del Protein truncation
JBR19 Exon 6 c.[564_565dupCC;566_577delTGCTGGGGAAGG] Frame shift, protein truncation
JBR20 Exon 5 c.328C/T (Q110X) Protein truncation
JBR21 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR22 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR23 Exon 6 c.397-7_399delCCTCCAGGTC Exon 6 skip (74 amino acid in-frame deletion)
JBR24 Exon 13 c.1533_1536delGATG Frame shift, protein truncation
JBR25 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR26 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR27 Exon 12 c.1347_1353dupCCACCCT Frame shift, protein truncation
JBR28 Exon 9 c.997_998dupTC Frame shift, protein truncation
JBR29 Exon 11 c.1177-5_1177-3delCTC Exon 11 skip (frame shift, protein truncation)
JBR30 Exon 7 c.769-771delTCC In-frame deletion
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Mutation reportdemonstrated together with the fragment found in normal
controls. EcoRI digestion yielded three fragments that were
recognised in normal controls (ﬁgure 2A), two large fragments
(10609 bp and (c) as expected in ﬁgure 2B) and a smaller frag-
ment (5988 bp as expected in ﬁgure 2B). In contrast, an aberrant
fragment was identiﬁed (d) in patient JBR18 and (e) in JBR14,
together with three fragments found in normal controls (ﬁgure
2A). The identical pattern of DNA fragments was conﬁrmed in
10 normal controls when digested with BamHI and EcoRI.
Clinical features of the BHDS patients in whom pneumothorax
and/or multiple lung cysts are the presenting feature
The clinical features of 25 patients who were shown to carry an
FLCN germline mutation in this study are summarised in table
2. In addition, to delineate the clinical features of patients with
BHDS more precisely, ﬁve previously reported patients were
included.
10 Accordingly, 30 patients with BHDS included six
males and 24 females. FLCN mutations were more frequently
identiﬁed in females although BHDS is believed to have no
gender predilection. This seems to be a selection bias since our
hospital is the main institution in Japan where patients with
suspected or diagnosed lymphangioleiomyomatosis are most
often referred to. The age at enrolment to the study was
45.7615.4 years old (mean6SD). All but one patient (29/30,
96.7%) had pneumothorax. Patient JBR19 had no information
on the side that experienced pneumothorax and then 20 of 28
(71.4%) experienced pneumothorax in both lungs. The majority
of patients (25 of 29; 86.2%) had pneumothorax repeatedly by
the time of their enrolment. Only one patient had no episode of
pneumothorax, but had multiple lung cysts. Only four patients
experienced one pneumothorax. The total median number of
pneumothorax episodes was three (range 0e8). No tendency for
the side of pneumothorax episodes was recognised. The most
frequent combination of phenotypes in the current group was
lung cysts without skin lesions and renal disease, and this was
demonstrated in 21 patients (70.0%). The median age of the 21
patients whose manifestation was only multiple lung cysts was
38 years old (range 23e85 years). All patients were screened for
skin lesion by dermatologists. Skin lesions were detected in
seven patients and only two patients had a histological
conﬁrmation: JBR16 (ﬁbrofolliculomas) and JBR30 (seborrhoeic
keratosis). All patients were screened for renal tumour by
utilising either ultrasonography or CT. Renal tumours were very
rare in this group and were found in only two patients, JBR15
with a single angiomyolipoma in the right kidney and JBR19
with a renal cancer (histopathological information was
unavailable). Three patients had carcinoma in a different organ,
including the breast, thyroid, and colon in their medical history.
Spectrum of germline FLCN mutations
FLCN mutations identiﬁed in 30 Japanese patients whose
presenting feature is pneumothorax and/or multiple lung cysts
are summarised and the features were compared with those
reported by the National Cancer Institute (NCI) group
(ﬁgure 3).
19 20 There were 18 unique mutations including two
genomic deletions in the current study population, while the
NCI group found 36 unique mutations. Deletion and insertion
were the mutation type that was most frequently detected in
both groups. The missense mutation, c.1523A>G (K508R), was
detected in the NCI group, but not in the current study popu-
lation. The mutations were distributed over the entire region in
both groups. However, the mutation seems to be found more
frequently in the 39 region of the FLCN gene, especially after
exon 9, in Japanese patients with BHDS (23/30, 76.7%). Both
exon 12 and 13 seem to be a hot spot in Japanese BHD patients
since c.1347_1353dupCCACCCT in exon 12 (9/30 ¼ 30.0%) and
c.1533_1536delGATG in exon13 (3/30 ¼ 10.0%) are the muta-
tions most frequently detected. On the other hand, exon 11 is
a hot spot and represents 50.0% (51/102) of the BHD families in
the NCI group. The majority of mutations in exon 11 occurred
within the mononucleotide tract of eight cytosine resides,
1278dupC or 1278delC, in the NCI group. However, only two
patients (2/30, 6.7%) in the current group had mutations in exon
11, while only one patient with 1278dupC was identiﬁed.
DISCUSSION
This study demonstrated, for the ﬁrst time, that not only
a small nucleotide alteration but also a large genomic deletion in
the FLCN gene causes BHDS. All of the previously reported
FLCN mutations have been identiﬁed with direct sequencing of
Figure 1 Analysis of the FLCN haploid
copy number. FLCN copy number status
(mean6SD) was determined by
quantitative polymerase chain reaction
(qPCR). The representative data from
exon 8 to exon 14 of the FLCN gene, and
the data of two reference genes, ZNF80
and GPR15, in two patients (JBR14 and
JBR18) and normal genomic DNA
(calibrator) are presented. JBR14
showed the gene dosage value close to
0.5 in 6 exons (exons 9 to 14),
suggesting a large genomic deletion
encompassing from exon 9 to exon 14.
On the other hand, JBR18 showed the
gene dosage value close to 0.5 only in
exon 14, suggesting a genomic deletion
of exon 14 and 39-untranslated region.
The gene dosage values of the remaining
exons (exons 1 to 7) for JBR14 and
JBR18 were close to 1.0 (data not
shown).
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Mutation reporteach exon of the FLCN gene. Recently, an FLCN mutation
database has been introduced: http://shingenedatabase.com/.
21
However, no large genomic deletion in the FLCN gene has
yet been found in this online database. However, the current
study has clearly shown that genetic testing for BHDS
should include methods to detect a germline deletion in the
FLCN gene.
qPCR has recently evolved as a valuable alternative to
Southern blotting to demonstrate a genomic deletion and has
successfully been applied for a genetic testing of Von-Hippel-
Lindau disease,
13 22 familial hypercholesterolaemia,
14 and long
QT syndrome.
16 qPCR analysis of the FLCN gene will hereafter
become one of the methods to be incorporated into genetic
testing for BHDS as well. Other techniques for the detection of
copy number changes or large deletions include the multiplex
ligation dependent probe ampliﬁcation (MLPA) method
consisting of ligation of oligonucleotide probes having identical
end sequences and subsequent multiplex PCR ampliﬁcation
using only one primer pair.
23 MLPA has been successfully
applied for the detection of large genomic deletion in LDL
receptor gene,
14 the PROSI gene in protein S deﬁciency,
15 and
the KCNQ1 and KCNH2 genes in long QT syndrome.
16 Since
the MLPA kit for the FLCN gene has recently become
commercially available, it may therefore be an alternative for
qPCR especially if a large number of samples are required to be
screened.
14
The Japanese patients in the present hospital based study
appear to have a distinct spectrum of FLCN mutations in
comparison to that of Caucasian patients with BHDS. FLCN
mutations seem to frequently occur in the 39-end of the FLCN
gene in the Japanese. The 39-end of the FLCN gene seems to have
a signiﬁcant relevance with FLCN function. Baba et al identiﬁed
the FLCN interacting protein, FNIP1, which binds to the C-
terminal region of FLCN.
24 Takagi et al
25 and Hasumi et al
26
identiﬁed FNIP-L/FNIP2, another FLCN interacting protein with
homology to FNIP1, and reported that the FNIP-L/FNIP2-
binding domain is also present in the C-terminal region of
FLCN. Germline FLCN mutations in the Japanese may directly
impair the interaction between FLCN and its binding proteins
and result in their disease phenotype.
The common mutation between the NCI group and the
current study is only the mutation of a cytosine insertion in the
Figure 2 Southern blot analysis of the
FLCN gene. Genomic DNA from two
patients (JBR14 and JBR18) and two
normal controls (N1 and N2) was
digested with either BamHI or EcoRI and
Southern blotting was performed using
32
P-labelled hBHD cDNA probe
25 (panel
A). Size marker (Mr) was shown on the
right. Distribution of 14 exons of the
FLCN gene, restriction sites of BamHI
and EcoRI, and expected length of
fragment are schematically presented
(panel B). The location of an
undetermined restriction site which is
involved in the generation of an aberrant
band is indicated by a dotted arrow.
Aberrant bands (a, b, c, d, and e)
expected to be generated with a large
genomic deletion (a thick shaded line) in
JBR14 and JBR18 are depicted with the
addition of a dotted line.
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Mutation reportC8 tract of exon 11. Accordingly, not only the distribution of
mutations but also the nucleotide alterations are different
between Caucasians and Japanese. One possible explanation for
the apparent difference in the FLCN mutations may be due to
the difference in an enrolment of the patients between the two
groups. NCI group enrolled primarily patients who had some
skin lesions or some renal tumours while the current study
enrolled patients with multiple lung cysts with or without
pneumothorax. In this context, the mutations detected in the
present study may be predisposed to the lung phenotype of
BHDS, although no phenotypeegenotype correlation has been
found so far.
19 20 Another possibility may be the racial difference
between Caucasians and Japanese since some of the inherited
tumour suppressor gene syndromes are reported to show racial
differences in mutations or clinical manifestationsdfor
example, APC gene mutations causing familial adenomatous
polyposis
27 28 and BRCA1/BRCA2 gene mutations seen in
African Americans and Caucasians.
29 30
Table 2 Clinical data of the 30 subjects who carry pathogenic FLCN mutation
Patient* Sex Agey
No. and
location of PTX
episodesz Skin lesion{ Renal disease
Family history
of PTX
Family history
of skin lesion
Family history
of renal disease
Medical
history**
Smoking
history
JBR1(B1) F 23(30) L(1) R(1) None None Yes No No Endometriosis,
PCOS, ovarian
cyst, lipoma
Never
JBR2(B2) F 16(38) L(3) R(3) None None Yes No No Myoma of the
uterus,
Ex-smoker 2.2
pack-years
JBR3(B3) F 25(40) L(3)R(2) None None Yes No Yes None Never
JBR4 F 49(80) R1 None None No No No None Never
JBR5(B6) F 35(37) L(1)R(1) None None Yes No No Myoma of the
uterus
Never
JBR6(B7) F 28(38) L(2)R(1) None None Yes No Yes Vocal cord
nodules, myoma
of the uterus,
carcinoma of the
thyroid gland
Ex-smoker 0.6
pack-years
JBR7 F 52(53) L(3) None None Yes No No Breast
carcinoma
Never
JBR8 M 33(33) R(1) None None No No No Non-functioning
adenoma of
adrenal gland
Never
JBR9 F (31) Never (lung
cyst)
None None No No No None Never
JBR10 F 78(85) L(1)R(1) None None No No No Colon cancer Never
JBR11 M 35(38) R(2) Nose None Yes No No None Never
JBR12 F 57(68) L(1)R(2) Face, neck Hydronephrosis
(L)
No No No Endometriosis Never
JBR13 F 27(32) L(2)R(2) None None Yes Yes No None Never
JBR14 F 27(31) L(1)R(6) None None No No No None Never
JBR15 F 38(43) L(1)R(2) None AML(R) No No No None Ex-smoker 2.7
pack-years
JBR16 F 26(54) L(4) FFs None Yes Yes No None Never
JBR17 M 34(34) L(5)R(2) None None No No No None Ex-smoker 18.8
pack-years
JBR18 F 16(46) L(4)R(4) None None Yes No No None Never
JBR19 F unknown(53) no details (2) None Cancer Yes No No None Never
JBR20 F 26(38) L(2)R(2) None None No No No None Ex-smoker 7.5
pack-years
JBR21 F 20(34) L(1)R(3) Chest None Yes No No Endometriosis Never
JBR22 F 41(59) R(1) Face, neck None Yes No No None Never
JBR23x M 25(40) L(1)R(2) None None Yes No No None Never
JBR24 F 52(52) L(1) None None No No No None Never
JBR25 M 29(32) L(1)R(3) None None Yes No No None Never
JBR26 F 21(23) L(2)R(2) None None No No No None Never
JBR27 F 65(66) R(2) None None Yes No No None Never
JBR28 F 24(44) L(2)R(1) None None Yes No No None Never
JBR29 F 51(53) L(1)R(1) Neck None Yes Yes No None Ex-smoker 4.7
pack-years
JBR30 M 29(66) L(3)R(3) Seborrhoeic
keratosis
None Yes No No Gallbladder
polyp
Never
JBR16 had FFs on the nose and JBR30 had seborrhoeic keratosis on the face and the neck.
Family history was obtained by an interview with the patient. FLCN mutation status of the family member was undetermined since they did not wish the genetic testing.
*The description in parentheses indicates the correspondence of the patient whose clinical data were already reported in the previous study.
10
yAge (years) at the ﬁrst PTX is shown. Age at the enrolment in this study is indicated in parenthesis.
zThe number of pneumothorax episode in parentheses.
xThe detailed clinical pictures of this case are described elsewhere.
18
{The locations of skin papules observed are indicated if the patient has no skin biopsy.
**Only medical histories considered to be relevant for BHDS are listed.
FFs, ﬁbrofolliculomas; L, left sided; PCOS, polycystic ovarian syndrome; PTX, pneumothorax; R, right sided.
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Mutation reportThe most frequent combination of phenotypes in the present
study group was lung cysts without skin lesions and renal
diseases, and was demonstrated in 21 patients (70.0%). All of the
patients had multiple lung cysts, and all but one patient had
a history of pneumothorax. Although various nucleotide alter-
ations were found in the FLCN gene including a germline dele-
tion, no apparent correlation between the BHD phenotype, even
in the lung phenotype, and genotype was found. Interestingly,
two patients with a germline deletion had pneumothorax
repeatedly and showed the highest number of occurrences of
pneumothorax in the study population; JBR14 had seven
pneumothorax episodes and JBR18 had eight. Further accumu-
lation of patients with a germline deletion is required to deter-
mine if it confers the severe lung phenotype.
Toro et al
20 and Schmidt etal
19 in NCI group reported that they
found 33 patients (32.4%) with three manifestations (skin lesion,
renal tumour, lung cysts/pneumothorax), but there were no
patients with three lesions in the present population. In their
study population, lung cysts were found on chest CT imaging in
80.4% (82/102) of families and 66.0% (144/218) of individuals
with BHDS, respectively. A history of spontaneous pneumo-
thoraxwasdemonstratedin49.0%(50/102)offamiliesand34.1%
(98/287) of individuals with BHDS, respectively. Although lung
cysts/pneumothorax is frequently demonstrated in the NCI
group, they had no patient with BHDS whose phenotype is
limited to the lung. As in the ﬁndings of the spectrum of germline
FLCN mutations, the differences in phenotype may also result
from the method of enrolment of subjects into the study. Alter-
natively, racial difference or age at the time of enrolment into the
study may be involved. Age related development of phenotype
was reported in BHDS. Skin papules are reported to develop after
the age of 30 years,
1 while patients with renal tumours increase
after the age of 40, although pneumothorax frequently occurs in
patients younger than 40 years.
6 More than half of the patients
(16/30; 53.3%) in the currentpopulation were more than 40 years
old and the majority (29/30; 96.7%) were more than 30 years old,
respectively, at the time of enrolment into this study. More
patients with the skin and renal phenotype should have been
included,butthecurrentpopulationmustbecarefullyfollowedto
determine if they develop any skin and renal disease in the future.
The radiological features of pulmonary cysts that can help to
differentiate BHDS from other cystic lung diseases have been
identiﬁed on chest CT images.
31 Accordingly, pulmonologists
should be aware of BHDS, especially if patients have a family
history of pneumothorax and characteristic cysts on chest CT
images irrespective of the skin and renal diseases. Genetic
testing, including qPCR of the FLCN gene, should therefore be
performed in order to make an earlier diagnosis of BHDS while,
in addition, subsequent care for the future development of renal
tumours may also be warranted.
Figure 3 Comparison of FLCN
germline mutation spectrum reported
by the National Cancer Institute (NCI)
group and the current study group. The
upper half shows the result of NCI
group
19 20 while the lower half is the
result of the current study (combined
with the previously reported result
10
and the present study). Symbols: red,
single nucleotide substitution; blue,
deletion and/or insertion; green, splice
site mutation; the bars on the bottom,
genomic deletion; a star, one patient.
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